Allos' Folotyn and Gloucster's Istodax: Exceptions That Prove The Rule?

ODAC continues to emphasize the importance of randomized controlled trials while supporting approval for two t-cell lymphoma drugs that conducted only singe-arm studies.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet